3-V Biosciences, Inc. is a privately-held biopharmaceutical company dedicated to discovering, developing and ultimately commercializing novel antiviral therapeutics that target host cell factors required for viral infection, thereby avoiding many of the shortcomings of traditional pathogen-directed approaches.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/05/12 | undisclosed | |||
| 01/05/15 | $28,500,000 | Series D |
Ally Bridge Group Rock Springs Capital | undisclosed |
